Jordan Kharofa1, Susan Tsai2, Tracy Kelly3, Clint Wood4, Ben George5, Paul Ritch5, Lauren Wiebe5, Kathleen Christians2, Douglas B Evans2, Beth Erickson6. 1. The University of Cincinnati, Department of Radiation Oncology, Cincinnati, United States. 2. Department of Surgery, Medical College of Wisconsin, Milwaukee, United States. 3. Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, United States. 4. Advanced Radiation Oncology, Greenwood, United States. 5. Department of Medical Oncology, Medical College of Wisconsin, Milwaukee, United States. 6. Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, United States. Electronic address: berickson@mcw.edu.
Abstract
PURPOSE: Neoadjuvant chemoradiation is an alternative to the surgery-first approach for resectable pancreatic cancer (PDA) and represents the standard of care for borderline resectable (BLR). MATERIALS AND METHODS: All patients with resectable and BLR PDA treated with neoadjuvant chemoradiation using IMRT between 1/2009 and 11/2011 were reviewed. Patients were treated to a customized CTV which included the primary mass and regional vessels. RESULTS: Neoadjuvant chemoradiation was completed in 69 patients (39 BLR and 30 resectable). Induction chemotherapy was used in 32 (82%) of the 39 patients with BLR disease prior to chemoXRT. All resectable patients were treated with chemoXRT alone. Following neoadjuvant treatment, 48 (70%) of the 69 patients underwent successful pancreatic resection with 47 (98%) being margin negative (RO). In 30 of the BLR patients who had arterial abutment or SMV occlusion, 19 (63%) were surgically resected and all had RO resections. The cumulative incidence of local failure at 1 and 2 years was 2% (95% CI 0-6%) and 9% (95% CI 0.6-17%) respectively. The median overall survival for all patients, patients undergoing resection, and patients without resection were 20, 26 and 11 months respectively. Sixteen (23%) of the 69 patients are alive without disease with a median follow-up of 47 months (36-60). CONCLUSION: Neoadjuvant chemoXRT can facilitate a margin negative resection in patients with localized PCa.
PURPOSE: Neoadjuvant chemoradiation is an alternative to the surgery-first approach for resectable pancreatic cancer (PDA) and represents the standard of care for borderline resectable (BLR). MATERIALS AND METHODS: All patients with resectable and BLR PDA treated with neoadjuvant chemoradiation using IMRT between 1/2009 and 11/2011 were reviewed. Patients were treated to a customized CTV which included the primary mass and regional vessels. RESULTS: Neoadjuvant chemoradiation was completed in 69 patients (39 BLR and 30 resectable). Induction chemotherapy was used in 32 (82%) of the 39 patients with BLR disease prior to chemoXRT. All resectable patients were treated with chemoXRT alone. Following neoadjuvant treatment, 48 (70%) of the 69 patients underwent successful pancreatic resection with 47 (98%) being margin negative (RO). In 30 of the BLR patients who had arterial abutment or SMV occlusion, 19 (63%) were surgically resected and all had RO resections. The cumulative incidence of local failure at 1 and 2 years was 2% (95% CI 0-6%) and 9% (95% CI 0.6-17%) respectively. The median overall survival for all patients, patients undergoing resection, and patients without resection were 20, 26 and 11 months respectively. Sixteen (23%) of the 69 patients are alive without disease with a median follow-up of 47 months (36-60). CONCLUSION: Neoadjuvant chemoXRT can facilitate a margin negative resection in patients with localized PCa.
Authors: Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess Journal: JAMA Date: 2007-01-17 Impact factor: 56.272
Authors: Mark S Talamonti; William Small; Mary F Mulcahy; Jeffrey D Wayne; Vikram Attaluri; Lisa M Colletti; Mark M Zalupski; John P Hoffman; Gary M Freedman; Timothy J Kinsella; Philip A Philip; Cornelius J McGinn Journal: Ann Surg Oncol Date: 2006-01-19 Impact factor: 5.344
Authors: Pietro Mancosu; Valentino Bettinardi; Paolo Passoni; Simone Gusmini; Stefano Cappio; Maria C Gilardi; Giovanni M Cattaneo; Michele Reni; Alessandro Del Maschio; Nadia Di Muzio; Ferruccio Fazio Journal: Radiother Oncol Date: 2008-05-15 Impact factor: 6.280
Authors: Edgar Ben-Josef; Anthony F Shields; Ulka Vaishampayan; Vainutis Vaitkevicius; Basil F El-Rayes; Patrick McDermott; Jay Burmeister; Todd Bossenberger; Philip A Philip Journal: Int J Radiat Oncol Biol Phys Date: 2004-06-01 Impact factor: 7.038
Authors: Michael T Milano; Steven J Chmura; Michael C Garofalo; Carla Rash; John C Roeske; Phillip P Connell; Oh-Hoon Kwon; Ashesh B Jani; Ruth Heimann Journal: Int J Radiat Oncol Biol Phys Date: 2004-06-01 Impact factor: 7.038
Authors: Jerome C Landry; Gary Y Yang; Joseph Y Ting; Charles A Staley; William Torres; Natia Esiashvili; Lawrence W Davis Journal: Med Dosim Date: 2002 Impact factor: 1.482
Authors: Matthew H G Katz; Peter W T Pisters; Douglas B Evans; Charlotte C Sun; Jeffrey E Lee; Jason B Fleming; J Nicolas Vauthey; Eddie K Abdalla; Christopher H Crane; Robert A Wolff; Gauri R Varadhachary; Rosa F Hwang Journal: J Am Coll Surg Date: 2008-03-17 Impact factor: 6.113
Authors: William F Regine; Kathryn A Winter; Ross A Abrams; Howard Safran; John P Hoffman; Andre Konski; Al B Benson; John S Macdonald; Mahesh R Kudrimoti; Mitchel L Fromm; Michael G Haddock; Paul Schaefer; Christopher G Willett; Tyvin A Rich Journal: JAMA Date: 2008-03-05 Impact factor: 56.272
Authors: Gauri R Varadhachary; Robert A Wolff; Christopher H Crane; Charlotte C Sun; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie Abdalla; Huamin Wang; Gregg A Staerkel; Jeffrey H Lee; William A Ross; Eric P Tamm; Priya R Bhosale; Sunil Krishnan; Prajnan Das; Linus Ho; Henry Xiong; James L Abbruzzese; Douglas B Evans Journal: J Clin Oncol Date: 2008-07-20 Impact factor: 44.544
Authors: Douglas B Evans; Gauri R Varadhachary; Christopher H Crane; Charlotte C Sun; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Huamin Wang; Karen R Cleary; Gregg A Staerkel; Chusilp Charnsangavej; Elizabeth A Lano; Linus Ho; Renato Lenzi; James L Abbruzzese; Robert A Wolff Journal: J Clin Oncol Date: 2008-07-20 Impact factor: 44.544
Authors: Jordan M Cloyd; Christopher H Crane; Eugene J Koay; Prajnan Das; Sunil Krishnan; Laura Prakash; Rebecca A Snyder; Gauri R Varadhachary; Robert A Wolff; Milind Javle; Rachna T Shroff; David Fogelman; Michael Overman; Huamin Wang; Anirban Maitra; Jeffrey E Lee; Jason B Fleming; Matthew H G Katz Journal: Cancer Date: 2016-05-31 Impact factor: 6.860
Authors: Chad A Barnes; Ashley N Krepline; Mohammed Aldakkak; Callisia N Clarke; Kathleen K Christians; Abdul H Khan; Bryan C Hunt; Paul S Ritch; Ben George; William A Hall; Beth A Erickson; Douglas B Evans; Susan Tsai Journal: J Gastrointest Surg Date: 2017-08-28 Impact factor: 3.452
Authors: Michael D Chuong; Jessica M Frakes; Nicholas Figura; Sarah E Hoffe; Ravi Shridhar; Eric A Mellon; Pamela J Hodul; Mokenge P Malafa; Gregory M Springett; Barbara A Centeno Journal: J Gastrointest Oncol Date: 2016-04
Authors: Mashaal Dhir; Gautam K Malhotra; Davendra P S Sohal; Nicholas A Hein; Lynette M Smith; Eileen M O'Reilly; Nathan Bahary; Chandrakanth Are Journal: World J Surg Oncol Date: 2017-10-10 Impact factor: 2.754
Authors: David Wittmann; William A Hall; Kathleen K Christians; Chad A Barnes; Neil R Jariwalla; Mohammed Aldakkak; Callisia N Clarke; Ben George; Paul S Ritch; Matthew Riese; Abdul H Khan; Naveen Kulkarni; John Evans; Beth A Erickson; Douglas B Evans; Susan Tsai Journal: Front Oncol Date: 2020-04-15 Impact factor: 6.244
Authors: Christopher Ryan Deig; Thomas Lee Sutton; Blake Beneville; Kristin Trone; Amanda Stratton; Ali N Gunesch; Amy Ivy Liu; Alaaeddin Alrohaibani; Maedeh Mohebnasab; Solange Bassale; Alison Grossblatt-Wait; Dove Keith; Fouad Attia; Erin W Gilbert; Charles D Lopez; Adel Kardosh; Emerson Y Chen; Kenneth G Bensch; Nima Nabavizadeh; Charles R Thomas; Skye C Mayo; Brett C Sheppard; Aaron Grossberg Journal: Cancers (Basel) Date: 2022-01-26 Impact factor: 6.639
Authors: Wenxin Zheng; Kinga B Skowron; Jukes P Namm; Byron Burnette; Christian Fernandez; Ainhoa Arina; Hua Liang; Michael T Spiotto; Mitchell C Posner; Yang-Xin Fu; Ralph R Weichselbaum Journal: Oncotarget Date: 2016-07-12